The evolution of percutaneous mitral valve repair therapy: Lessons learned and implications for patient selection

Roy Beigel, Nina C. Wunderlich, Saibal Kar, Robert J. Siegel*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Mitral regurgitation (MR) is the most common valve disease in the United States. However, a significant number of patients are denied surgery due to increased age, poor ventricular function, or associated comorbidities, putting them at high risk for adverse events. Moreover, the benefit of surgery for MR is unclear in patients with functional (secondary) MR. Recently, percutaneous repair of the mitral valve with a particular device (MitraClip, Abbott, Menlo Park, California) has emerged as a novel therapeutic option for patients with secondary MR or those deemed to be high risk for surgery. We review data from its initial concept through clinical trials and current data available from several registries. We focused on lessons learned regarding adequate patient selection, along with current and future perspectives on the use of device therapy for the treatment of MR.

Original languageEnglish
Pages (from-to)2688-2700
Number of pages13
JournalJournal of the American College of Cardiology
Volume64
Issue number24
DOIs
StatePublished - 23 Dec 2014

Funding

FundersFunder number
Israel Heart Society
St. Jude Medical

    Keywords

    • mitral valve
    • mitral valve annuloplasty
    • mitral valve insufficiency
    • outcomes assessment
    • patient selection

    Fingerprint

    Dive into the research topics of 'The evolution of percutaneous mitral valve repair therapy: Lessons learned and implications for patient selection'. Together they form a unique fingerprint.

    Cite this